| Outcome Measures: |
Primary: Proportion of T2DM patients with high medication adherence at Week 24, 24 weeks | Secondary: The effectiveness of linagliptin and acarbose on glycemic control evaluated by reducing HbA1c during a 24 week follow-up in two groups, 24 weeks|Proportion of T2DM patients achieving a therapeutic glycemic response defined as HbA1c < 7.0% or a lowering of HbA1c ≥ 0.5%, 24 weeks|To compare the composite endpoint (proportion of achieving HbA1c < 7.0% without gastrointestinal adverse events (GI AEs) and without an investigator defined hypoglycaemic event), 24 weeks|Patient satisfaction by Diabetes Treatment Satisfaction Questionnaire (DTSQ) among linagliptin and acarbose initiators. The DTSQ would be completed at routine physician visits since initiation of the drug, 24 weeks
|
| Locations: |
No.731 Hospital of China Aerospace Science & Industry Corp., Beijing, 100074, China|Affiliated Hospital of Chengdu University, Chengdu, 610081, China|ChongQing The Fourth Hospital, Chongqing, 400014, China|Dongying People's Hospital, Dongying, 257000, China|Huai'an first people's hospital, Huai'an, 223300, China|Nanjing Drum Tower Hospital, Nanjing, 210008, China|Zhongda Hospital Southeast University, Nanjing, 210009, China|Shanghai TCM-Integrated Hospital, Shanghai, 200000, China|Southern Medical University Shenzhen Hospital, Shenzhen, 518110, China|Zhangjiagang First People Hospital, Suzhou, 215699, China
|
